Karen A Autio

Karen A Autio

UNVERIFIED PROFILE

Are you Karen A Autio?   Register this Author

Register author
Karen A Autio

Karen A Autio

Publications by authors named "Karen A Autio"

Are you Karen A Autio?   Register this Author

18Publications

368Reads

43Profile Views

Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-target Effects with Reduced Off-tumor Toxicity for Use in Immuno-Oncology.

Clin Cancer Res 2019 Oct 10. Epub 2019 Oct 10.

Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-19-1457DOI Listing
October 2019

Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors.

J Clin Oncol 2016 10;34(29):3562-3569

Aung Naing, Rivka R. Colen, David S. Hong, and Nizar M. Tannir, MD Anderson Cancer Center, Houston; Kyriakos P. Papadopoulos and Drew R. Rasco, START Center for Cancer Care, San Antonio, TX; Karen A. Autio, Memorial Sloan Kettering Cancer Center, New York, NY; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Manish R. Patel, Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL; Deborah J. Wong, University of California Los Angeles, Los Angeles; Melinda Whiteside, John B. Mumm, Ivan H. Chan, Peter Van Vlasselaer, and Martin Oft, ARMO BioSciences, Redwood City, CA; Gerald S. Falchook, Sarah Cannon Research Institute at HealthONE, Denver, CO; Shubham Pant, Oklahoma University, Oklahoma City, OK; and Johanna C. Bendell, Todd M. Bauer, and Jeffrey R. Infante, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.68.1106DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5657013PMC
October 2016

Targeting the androgen receptor in prostate and breast cancer: several new agents in development.

Endocr Relat Cancer 2015 Jun 26;22(3):R87-R106. Epub 2015 Feb 26.

Breast Medicine ServiceDepartment of Medicine, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, New York, New York 10065, USAGenitourinary Oncology ServiceDepartment of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10065, USAWeill Cornell Medical College1300 York Avenue, New York, New York 10065, USA Breast Medicine ServiceDepartment of Medicine, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, New York, New York 10065, USAGenitourinary Oncology ServiceDepartment of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10065, USAWeill Cornell Medical College1300 York Avenue, New York, New York 10065, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1530/ERC-14-0543DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4714354PMC
June 2015

High-risk prostate cancer-classification and therapy.

Nat Rev Clin Oncol 2014 Jun 20;11(6):308-23. Epub 2014 May 20.

Genitourinary Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, Weill Cornell Medical College, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2014.68DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4508854PMC
June 2014

Pain palliation measurement in cancer clinical trials: the US Food and Drug Administration perspective.

Cancer 2014 Mar 5;120(5):761-7. Epub 2013 Dec 5.

Cancer Outcomes Research Program, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.28470DOI Listing
March 2014

Repetitively dosed docetaxel and ¹⁵³samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer.

Cancer 2013 Sep 13;119(17):3186-94. Epub 2013 Jun 13.

Genitourinary Oncology Service, Sidney Kimmel Center for Prostate and Urologic Cancers, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.28103DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3775970PMC
September 2013

Prevalence of pain and analgesic use in men with metastatic prostate cancer using a patient-reported outcome measure.

J Oncol Pract 2013 Sep 25;9(5):223-9. Epub 2013 Jun 25.

Memorial Sloan-Kettering Cancer Center, New York; Weill Cornell Medical College, New York, NY; Knight Cancer Institute, Oregon Health & Science University, Portland, OR; Duke University Medical Center, Durham; Cancer Outcomes Research Program, University of North Carolina, Chapel Hill, NC; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore; US Food and Drug Administration, Silver Spring, MD; and University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.2013.000876DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3994234PMC
September 2013

Monitoring the clinical outcomes in advanced prostate cancer: what imaging modalities and other markers are reliable?

Semin Oncol 2013 Jun;40(3):375-92

Genitourinary Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2013.04.008DOI Listing
June 2013

Targeting bone physiology for the treatment of metastatic prostate cancer.

Clin Adv Hematol Oncol 2013 Mar;11(3):134-43

Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3938391PMC
March 2013

Therapeutic strategies for bone metastases and their clinical sequelae in prostate cancer.

Curr Treat Options Oncol 2012 Jun;13(2):174-88

Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-012-0190-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3652976PMC
June 2012

Low bone mineral density in adolescents with beta-thalassemia.

Ann N Y Acad Sci 2005 ;1054:462-6

Department of Pediatrics, New York-Presbyterian Hospital / Weill Medical College of Cornell University, New York, New York 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1196/annals.1345.063DOI Listing
July 2006

Low bone mass in prepubertal children with thalassemia major: insights into the pathogenesis of low bone mass in thalassemia.

J Pediatr Endocrinol Metab 2004 Oct;17(10):1415-21

Department of Pediatrics, The New York-Presbyterian Hospital/Weill Medical College of Cornell University, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1515/jpem.2004.17.10.1415DOI Listing
October 2004

Low bone mass in prepubertal children with thalassemia major: insights into the pathogenesis of low bone mass in thalassemia.

J Pediatr Endocrinol Metab 2004 Oct;17(10):1415-21

Department of Pediatrics, The New York-Presbyterian Hospital/Weill Medical College of Cornell University, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1515/jpem.2004.17.10.1415DOI Listing
October 2004